文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

三金片治疗急性单纯性下尿路感染(下焦湿热证):随机、双盲、双模拟、阳性药平行对照、多中心临床试验方案

Sanjin tablets for acute uncomplicated lower urinary tract infection (syndrome of dampness-heat in the lower jiao): protocol for randomized, double-blind, double-dummy, parallel control of positive drug, multicenter clinical trial.
PubMed 文献 · Trials · 2019-07-19

本研究为随机、双盲、双模拟、阳性药平行对照、多中心临床试验方案,拟纳入252例急性单纯性下尿路感染(下焦湿热证)患者,按1:1:1随机分为三组,分别接受三金片+左氧氟沙星片模拟剂、左氧氟沙星片+三金片模拟剂、或前5天三金片+左氧氟沙星片后2天三金片+左氧氟沙星片模拟剂,疗程7天,随访1-2次,主要结局为症状有效率与复发率,次要结局包括尿白细胞、细菌学检查及安全性评估。

要点

  • 方案拟纳入252例急性单纯性下尿路感染(下焦湿热证)患者,按1:1:1随机分三组。
  • 试验组用三金片+左氧氟沙星片模拟剂,对照组1用左氧氟沙星片+三金片模拟剂。
  • 对照组2前5天用三金片+左氧氟沙星片,后2天用三金片+左氧氟沙星片模拟剂。

核心结论

  • 本方案将提供三金片治疗急性单纯性下尿路感染的有效性和安全性研究数据。
  • 首要目的是确定三金片能否减少抗生素的使用,其次是确定三金片能否替代抗生素的使用。
  • 将在治愈后评估复发率,以确定三金片能否降低复发率。

研究设计与样本

  • 研究设计为随机、双盲、双模拟、阳性药平行对照、多中心临床试验。
  • 计划纳入252例急性单纯性下尿路感染(下焦湿热证)患者,按1:1:1随机分为三组。
  • 试验组接受三金片+左氧氟沙星片模拟剂;对照组1接受左氧氟沙星片+三金片模拟剂;对照组2前5天接受三金片+左氧氟沙星片、后2天接受三金片+左氧氟沙星片模拟剂。
  • 各组治疗7天,随访1-2次;主要结局为症状有效率和复发率,次要结局包括尿白细胞、细菌学检查及安全性评估,在基线和治疗后评估。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Acute uncomplicated lower urinary tract infection (UTI) is one of the most common bacterial infections. Patients usually present with dysuria, urinary urgency, urinary frequency, and suprapubic pain or tenderness. Approximately 150 million people are diagnosed with UTI each year worldwide. The high recurrence rate of lower UTI is a common problem of clinical treatment. The misuse of antibiotics has led to the emergence of a number of resistant bacterial strains. Thus, traditional Chinese medicine is considered as an alternative option for treating acute uncomplicated lower UTI. Thus, this study aims to evaluate the efficacy and safety of Sanjin tablets (SJT) for the treatment of acute uncomplicated lower UTI, explore whether SJT can reduce or substitute the use of antibiotics, and reduce the recurrence rate in the treatment of acute uncomplicated lower UTI. METHODS/DESIGN: In this study, a randomized, double-blind, double-dummy, parallel control of positive drug, multicenter clinical study will be established. A total of 252 patients with acute uncomplicated lower UTI (syndrome of dampness-heat in the lower jiao) will be randomly allocated in the ratio of 1:1:1 to three groups: experimental group; control group 1; and control group 2. The experimental group receives Sanjin tablets plus levofloxacin tablets (LT) placebo; the control group 1 receives LT plus SJT placebo; and the control group 2 receives SJT plus LT on the first five days, SJT plus LT placebo on the last two days. Each group will be treated for seven days and followed-up 1-2 times. The primary outcome measures of effective rate and recurrence rate are symptoms. Secondary outcome measures of effective rate and recurrence rate are the urine leukocytes, bacteriology examination, and safety assessment. Outcomes will be assessed at baseline and after treatment. DISCUSSION: This study protocol will provide the research data of efficacy and safety of SJT for the treatment of acute uncomplicated lower UTI. The first aim is to determine whether Sanjin tablets can reduce the use of antibiotics; the second aim is to determine whether Sanjin tablets can substitute the use of antibiotics. The recurrence rate will be assessed after cured to determine whether SJT can reduce the recurrence rate. The results of this study will improve the rational use of drugs, especially the rational application of antibiotics. It will also enable safety evaluation from laboratory indices and adverse events, which will provide reliable evidence for clinical treatment. TRIAL REGISTRATION: ClinicalTrials.gov, NCT03658291 . Registered on 4 September 2018.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Lyu J, Xie YM, Gao Z, et al. Sanjin tablets for acute uncomplicated lower urinary tract infection (syndrome of dampness-heat in the lower jiao): protocol for randomized, double-blind, double-dummy, parallel control of positive drug, multicenter clinical trial. Trials. 2019. PMID: 31324199. doi:10.1186/s13063-019-3539-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。